Aslan Pharmaceuticals Ltd ADR (ASLN)

Jul 18, 2024, 7:55 AM EDT - 6 months ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

CERO ONVO

Jul 17, 2024, 7:25 AM EDT - 6 months ago

ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation

Jul 15, 2024, 7:30 AM EDT - 6 months ago

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal

May 21, 2024, 7:00 AM EDT - 8 months ago

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference

May 9, 2024, 7:00 AM EDT - 9 months ago

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 7:30 AM EDT - 9 months ago

ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

May 2, 2024, 9:00 AM EDT - 9 months ago

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

Apr 30, 2024, 7:00 AM EDT - 9 months ago

ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab

Apr 22, 2024, 8:45 AM EDT - 9 months ago

ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

Apr 19, 2024, 5:10 PM EDT - 9 months ago

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice

Apr 12, 2024, 8:00 AM EDT - 10 months ago

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 27, 2024, 8:07 AM EDT - 10 months ago

Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders

Mar 12, 2024, 2:34 PM EDT - 11 months ago

ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering

Feb 29, 2024, 7:00 AM EST - 11 months ago

ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat

Jan 8, 2024, 6:45 AM EST - 1 year ago

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Jan 2, 2024, 7:00 AM EST - 1 year ago

ASLAN Pharmaceuticals Announces Participation in January Investor Conferences

Dec 12, 2023, 7:00 AM EST - 1 year ago

ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs

Nov 3, 2023, 7:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit

Oct 27, 2023, 8:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 18, 2023, 7:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

Oct 13, 2023, 9:30 AM EDT - 1 year ago

ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress

Sep 22, 2023, 7:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress

Sep 7, 2023, 7:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 11, 2023, 7:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 6, 2023, 8:22 AM EDT - 1 year ago

Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatment

Jul 6, 2023, 7:55 AM EDT - 1 year ago

Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis

Jul 5, 2023, 4:30 PM EDT - 1 year ago

ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis

Jun 23, 2023, 7:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab's Unique Mechanism of Action in the Treatment of Atopic Dermatitis

Jun 22, 2023, 7:30 AM EDT - 1 year ago

ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan

Jun 1, 2023, 7:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Apr 28, 2023, 7:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Mar 28, 2023, 7:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements

Mar 24, 2023, 7:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 14, 2023, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting

Mar 10, 2023, 7:00 AM EST - 2 years ago

ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

Feb 28, 2023, 7:00 AM EST - 2 years ago

ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata

Feb 24, 2023, 6:00 AM EST - 2 years ago

ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M

Feb 24, 2023, 5:59 AM EST - 2 years ago

ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients

Nov 21, 2022, 7:00 AM EST - 2 years ago

ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference

Oct 28, 2022, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 14, 2022, 7:15 AM EDT - 2 years ago

ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

Sep 13, 2022, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Announces Acceptance of Two Late-Breaking Abstracts for e-Poster Presentation at the 51st Annual European Society for Dermatological Research Meeting

Sep 7, 2022, 6:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Multiple Posters at the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress

Sep 2, 2022, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 25, 2022, 7:03 AM EDT - 2 years ago

ASLAN PHARMACEUTICALS SIGNS LICENSE AGREEMENT WITH BELLE.AI TO USE BELLESTUDY™ IMAGE CAPTURE SOFTWARE IN ATOPIC DERMATITIS CLINICAL TRIALS

Aug 25, 2022, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Signs License Agreement With Belle.ai to Use belleStudy™ Image Capture Software in Atopic Dermatitis Clinical Trials

Aug 22, 2022, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals to Host a Hybrid R&D Day on September 15, 2022

Aug 12, 2022, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Jun 7, 2022, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis

May 31, 2022, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals to Participate in Fireside Chat at Jefferies Global Healthcare Conference